MedTrace Logo

Bedtime Device Restriction and Desmopressin in PMNE.

NCT07776977 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-08-24

No results posted yet for this study

Summary

This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.

Conditions

  • Primary Monosymptomatic Nocturnal Enuresis

Interventions

DRUG

Desmopressin

Oral desmopressin administered at bedtime for 8 weeks for treatment of primary monosymptomatic nocturnal enuresis.

BEHAVIORAL

Bedtime digital-device restriction

Restriction of digital-device use, including smartphones, tablets, televisions, computers, and video games, for at least 60 minutes before habitual bedtime during the 8-week treatment period.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Abul-fotouh Ahmed · Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-20
Primary Completion
2027-05-31
Completion
2027-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776977 on ClinicalTrials.gov